AnaptysBio, Inc. (ANAB) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ANAB Revenue Growth
ANAB Revenue Analysis (2014–2025)
As of May 8, 2026, AnaptysBio, Inc. (ANAB) generated trailing twelve-month (TTM) revenue of $234.6 million, reflecting explosive growth of +151.1% year-over-year. The most recent quarter (Q4 2025) recorded $108.2 million in revenue, up 41.8% sequentially.
Looking at the longer-term picture, ANAB's 5-year compound annual growth rate (CAGR) stands at +25.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $234.6 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), ARQT (+95.3% YoY), and DAWN (+20.6% YoY), ANAB has outperformed the peer group in terms of revenue growth. Compare ANAB vs RCUS →
ANAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ANABCurrent | $235M | +151.1% | +25.6% | 20.4% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 DAWN | $158M | +20.6% | - | -80.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
ANAB Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $234.6M | +157.0% | $232.2M | 99.0% | $47.9M | 20.4% |
| 2024 | $91.3M | +432.0% | $-72,560,000 | -79.5% | $-114,949,000 | -125.9% |
| 2023 | $17.2M | +66.8% | $-115,126,000 | -671.0% | $-164,411,000 | -958.3% |
| 2022 | $10.3M | -83.7% | $-78,511,000 | -763.2% | $-115,154,000 | -1119.4% |
| 2021 | $63.2M | -15.8% | $-35,321,000 | -55.9% | $-56,814,000 | -89.9% |
| 2020 | $75.0M | +837.5% | $-5,025,000 | -6.7% | $-23,879,000 | -31.8% |
| 2019 | $8.0M | +60.0% | $-91,338,000 | -1141.7% | $-107,432,000 | -1342.9% |
| 2018 | $5.0M | -50.0% | $-51,196,000 | -1023.9% | $-66,721,999 | -1334.4% |
| 2017 | $10.0M | -40.1% | $-19,443,000 | -194.4% | $-28,781,000 | -287.8% |
| 2016 | $16.7M | -5.0% | $1.3M | 7.6% | $-3,025,000 | -18.1% |
See ANAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonANAB — Frequently Asked Questions
Quick answers to the most common questions about buying ANAB stock.
Is ANAB's revenue growth accelerating or slowing?
ANAB revenue is accelerating at +151.1% year-over-year, exceeding the 5-year CAGR of +25.6%. TTM revenue reached $235M. Growth momentum has increased versus prior periods.
What is ANAB's long-term revenue growth rate?
AnaptysBio, Inc.'s 5-year revenue CAGR of +25.6% reflects the sustained expansion pattern. Current YoY growth of +151.1% is above this long-term average.
How is ANAB's revenue distributed by segment?
ANAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.